SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven low-cap memecoin on Solana, with investors actively discussing its rapid growth and the developer's commitment to community engagement through frequent airdrops and transparency. Supporters are rallying behind the project's 'dumb send' philosophy, frequently comparing its early-stage potential to other successful runners while focusing on social media trending and viral expansion.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened community engagement driven by anticipation surrounding ongoing monthly burn initiatives and the development of new ecosystem projects. Supporters are closely watching the chart for signs of a turnaround, frequently discussing the potential for a long-term recovery and increased utility within the blockchain.

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM Resorts International is drawing attention following the submission of a significant 2.3 billion dollar proposal for a new casino license in New York, a move seen by the community as a key strategy to expand its East Coast footprint. While investors weigh this regulatory catalyst against broader economic concerns, discussions remain split between the stock's long-term potential in the gaming sector and the immediate impact of market-wide volatility on consumer discretionary spending.

Nomad Foods Ltd. operates as a holding company, which manufactures and sells frozen foods for human consumption. The firm offers its products under the brands LUTOSA, la Cocinera, Birds Eye, Iglo, and Findus. The company was founded by Noam Gottesman and Sir Martin E. Franklin on April 1, 2014 and is headquartered in Woking, the United Kingdom.

Nomad Foods Limited

Nomad Foods is trending as investors weigh its attractive dividend yield, aggressive share buyback programs, and low valuation against sector-wide headwinds and concerns about debt levels. The community is actively debating whether these factors signal a deep-value opportunity or a long-term value trap in the frozen food space.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social media attention as the community debates its long-term potential following recent academic recognition for its post-quantum security architecture. Investors are actively discussing the project's institutional utility and price action, with many using the current market movement as an opportunity to accumulate tokens while others remain skeptical about the asset's historical performance.

Optical Cable Corp. engages in the business of manufacturing fiber optic and copper data communication cabling and connectivity solutions primarily for the enterprise market and various harsh environment, specialty markets, and the wireless carrier market offering integrated suites of high-quality products which operate as a system solution or seamlessly integrate with other components. Its products include fiber optic and copper cabling, hybrid cabling, fiber optic and copper connectors, specialty fiber optic, copper and hybrid connectors, fiber optic and copper patch cords, pre-terminated fiber optic and copper cable assemblies, racks, cabinets, datacom enclosures, patch panels, face plates, multimedia boxes, fiber optic reels, and other cable and connectivity management accessories. The company was founded on June 10, 1983 and is headquartered in Roanoke, VA.

Optical Cable Corp.

Optical Cable Corp is trending as investors monitor its role in the data center and fiber infrastructure boom, with the community closely tracking potential execution of its strategic partnership with Lightera. While sentiment remains divided between those betting on long-term value from increased fiber demand and those wary of the stock's low-float volatility and historical revenue headwinds, the ticker continues to attract attention during retail momentum cycles.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors is trending as investors weigh its role as a "picks-and-shovels" play in the automotive and industrial AI buildout against recent analyst downgrades citing inventory and demand concerns. The community is actively debating whether its recent price action signals a long-term value opportunity or a trap amid broader volatility in the semiconductor sector.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2025 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as the Michael Jackson biopic, Michael, generates massive global anticipation and tracking figures that significantly outperform initial projections, fueling community excitement over a potential blockbuster. Investors are closely monitoring these box office tailwinds alongside speculation about a potential buyout as the studio actively pursues strategic consolidation following a major leadership incentive filing.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

The $AIRCOIN community is rallying behind the project's long-term vision, emphasizing its unique 'Airlock' mechanism which has over 38% of the supply locked on-chain to demonstrate deep investor conviction. Supporters frequently highlight the project's historical lore, battle-tested leadership, and growing treasury as key differentiators that position it as a durable, fundamentally-driven alternative to short-lived meme trends.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant community buzz through its long-standing presence on the Solana network, with holders actively promoting its organic growth and whale accumulation trends. The community remains highly engaged by leveraging the project's playful 'dad joke' branding to maintain visibility and momentum across various social platforms.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.

Power, Compute and Breakthrough Science

Today’s headlines underscore a decisive shift toward owning the infrastructure, power, and materials that will underpin the next phase of the AI economy, including $KBLB, $VCIG, $CANF, $ASNS, $BW, and $APLD

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CANF Stock Soar 25% Today?

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Equity

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

This Microcap Just Locked Up New IP in a Massive Pharma Market

In biotechnology, intellectual property wins often act as quiet but powerful catalysts, particularly when they extend a platform into new therapeutic categories or unlock access to large international markets. As competition intensifies and pipelines mature, patent protection remains a key driver of long-term value, especially for companies advancing novel mechanisms with broad clinical applicability.Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF) are surging Friday after the company announced it was granted a new patent in Brazil covering the treatment of sexual dysfunction. The ...

<ul class="summary-bullets"><li>Can-Fite is advancing its proprietary A3AR agonist platform across multiple indications, including oncology and inflammatory diseases.</li><li>The new patent expands Can-Fite’s IP coverage in Brazil and opens up potential commercialization opportunities in the Latin American market.</li><li>On Tuesday, the company approved a 1-for-3,000 reverse split effective Jan. 5, 2026, on the Tel Aviv Stock Exchange, alongside an ADS ratio change on the NYSE at a 1-for-20 reverse split.</li></ul>NYSE-listed shares of Can-Fite BioPharma (CANF) surged 50% in premarket trading on Friday, after the company secured a Brazilian patent for its treatment of sexual dysfunction, opening the door to potential commercialization opportunities in Latin America.<a href="https://stocktwits.com/symbol/CANF">Can-Fite BioPharma</a> announced that Brazil’s Patent Office has granted a patent covering the use of its A3 adenosine receptor (A3AR) agonists for the treatment of sexual dysfunction. The new patent expands Can-Fite’s IP coverage in Brazil, a key Latin American pharmaceutical market with increasing demand for treatments targeting sexual health.<h2 class="st-heading-2">Can-Fite’s A3AR Agonist Platform</h2>Sexual dysfunction is linked to vascular, inflammatory, and metabolic pathways, and Can-Fite’s preclinical and clinical research suggests that A3AR activation may help regulate key signaling mechanisms involved in erectile and sexual function. Can-Fite is advancing its proprietary A3AR agonist platform across multiple indications, including oncology and inflammatory diseases, while exploring additional non-oncologic applications.“The grant of this Brazilian patent further validates the therapeutic versatility of A3 adenosine receptor agonists and expands our intellectual-property footprint in a major pharmaceutical market. This patent complements our broader clinical and preclinical programs and may create future partnering or commercialization opportunities in Latin America,” said Pnina Fishman, Chairperson and Chief Scientific Officer at Can-Fite BioPharma.<h2 class="st-heading-2">Reverse Stock Spilt</h2>On Tuesday, Can-Fite BioPharma approved a 1-for-3,000 reverse split of its ordinary shares, which will&nbsp;be recorded on the Tel Aviv Stock Exchange on January 2, 2026, with trading in the newly consolidated shares set to begin on January 5, 2026.At the same time, Can-Fite will adjust the ratio of its American Depositary Shares (ADS) traded on the NYSE. The ADS ratio will change from one ADS representing 300 ordinary shares to one ADS representing two ordinary shares, an adjustment equivalent to a 1-for-20 ADS split.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user was speculating on the stock price post reverse split.<stembedurl>https://stocktwits.com/Dansaidso/message/640149218</stembedurl>Year-to-date, the stock has been under heavy selling pressure, losing more than 85%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/mag-7-2025-review-on-charts/cLeU7wOREwN">As 2025 Bids Adieu, A Look At How Mag 7 Stocks Are Positioned On Charts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stocks, shares background - stock photo (representative image courtesy of Sean Gladwell via Getty Images)

Can-Fite BioPharma Shares Surged 50% In Pre-Market On Brazilian Patent Win

The company said it was granted a patent covering the use of its A3 adenosine receptor agonists for the treatment of sexual dysfunction in Brazil.

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Current Price	$2.91
Prev Close	$2.91
Open	$2.97
Dividend Yield	0.00%
50-Day Moving Average	$3.70
Beta	0.60
Avg. Volume	1.87M
PE Ratio	-0.23

52-Week High	$24.00
52-Week Low	$2.87
Market Capitalization	$6.23M
EPS (Annual)	-$12.03
Price to Book	0.68
Revenue Per Employee	$81,642.60

CANF
Can-Fite BioPharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest CANF News

CANFCan-Fite BioPharma Ltd.